Ken Griffin Checkpoint Therapeutics, Inc. Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $43,525 - $452,323	-42,672 Reduced 71.97%	16,620 $17,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $116,907 - $213,325	-120,523 Reduced 67.03%	59,292 $61,000
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $87,350 - $185,549	57,092 Added 46.52%	179,815 $318,000
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $218,701 - $363,958	-81,605 Reduced 39.94%	122,723 $381,000
Q3 2021 Nov 15, 2021	BUY	$2.5 - $3.53 $199,612 - $281,852	79,845 Added 64.14%	204,328 $674,000
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $145,253 - $196,953	61,548 Added 97.8%	124,483 $367,000
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $163,631 - $261,809	62,935 New	62,935 $198,000
Q3 2020 Nov 16, 2020	SELL	$1.62 - $4.24 $35,983 - $94,178	-22,212 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.19 - $2.27 $26,432 - $50,421	22,212 New	22,212 $44,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $302M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.